The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05722886
Recruitment Status : Recruiting
First Posted : February 10, 2023
Last Update Posted : March 20, 2024
University of Manchester
University of Birmingham
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche
Information provided by (Responsible Party):
Cancer Research UK

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2029
Estimated Study Completion Date : October 2029